WO2021242142A1 - Composition pharmaceutique aqueuse stable - Google Patents
Composition pharmaceutique aqueuse stable Download PDFInfo
- Publication number
- WO2021242142A1 WO2021242142A1 PCT/RU2021/000221 RU2021000221W WO2021242142A1 WO 2021242142 A1 WO2021242142 A1 WO 2021242142A1 RU 2021000221 W RU2021000221 W RU 2021000221W WO 2021242142 A1 WO2021242142 A1 WO 2021242142A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hexapeptide
- composition
- present
- inhalation
- lungs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- NsNs RF patents
- Non-exclusive examples of adjuvants for use in the compositions of the present invention include purified water, water for injection, buffer systems for maintaining the pH value at the level of 3.0-8.5, regulators of the tonicity of solutions, antimicrobial preservatives, surfactants, stabilizing agents, emulsifiers.
- the selection of excipients for use in the compositions of the present invention can be carried out on the basis of the following criteria: the excipient should not affect the main therapeutic effect of the composition, should not be toxic in the amounts used and should not adversely affect the functions of the mucous membrane of the respiratory tract and its ciliated epithelium ...
- nebulizer refers to an inhalation device that converts a liquid drug for nebulization into a dispersion in a gas medium for delivery of an active substance to the lungs.
- nebulizers include compressor, ultrasonic, or other types of nebulizers.
- the medicament of the present invention can be manufactured by methods well known in the art and in accordance with recognized pharmaceutical procedures, for example, as described in the Remington Pharmaceutical Science Directory, 17th edition, ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, PA, 18th edition (Remington's Pharmaceutical Sciences, seventeenth edition, ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, Pa., Eighteenth edition, 1990).
- the medicament is for the treatment of pneumonia.
- the example illustrates the pharmacokinetics of hexapeptide (I) when administered by inhalation of the compositions of the present invention.
- mice of the C576I line were injected by inhalation over 2 minutes with 20 ⁇ l of aqueous pharmaceutical compositions of the present invention (from example 1), pH 4, 8-5, 2, containing 0.1; 1; ten; 100 mg / ml diacetate hexapeptide (I), which corresponds to doses of 0.1; 1; NS; 100 mg / kg. Measured the content of hexapeptide (I) in the lungs as described in example 4.
- Severe fatal pneumonia was induced by the addition of the immunosensitizer alpha-galactosylceramide as described in Aoyagi T et al, Shock. 2019, 52 (1): 83-91.
- Intratracheal administration of alpha-galactosylceramide (1 ⁇ g / mouse) to mice and 24 hours later LPS (E. coli; 300 ⁇ g / mouse) with the addition of a complex of immunosensitizers muramyldipeptide G2 and Freund's complete adjuvant causes pneumonia, acute respiratory distress syndrome and pulmonary edema.
- RNA was extracted, and the expression of the IL-6 gene in the lungs was assessed by PCR using a CFX-96 detecting amplifier (Biorad, USA) using specific primers and fluorescent probes.
- the GAPDH gene was chosen as a reference gene. The results are presented in Table 8 as the mean ⁇ error of the mean x 10 6 copies of IL-6 cDNA.
- Comparison of the expression of IL-6 in groups 2 and 3 shows that inhalation of hexapeptide (I) in the stable aqueous pharmaceutical composition of the present invention significantly reduces the expression of IL-6 in the lungs by 2.7 times (p ⁇ 0.05) compared with injections of hexapeptide (I) at the same dose.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des compositions pharmaceutiques aqueuses stables pour inhalation, contenant de 0,1 mg/l à 100 mg/l d'un hexapeptide de la formule H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) ou son sel phamaceutiquement acceptable, de préférence du diacétate, et possédant un pH de 3,0 à 8,5; l'invention concerne également un processus de production desdites compositions, l'utilisation desdites compositions dans la production d'agents médicamenteux pour traiter des maladies pulmonaires, et ainsi que des procédés de traitement de maladies pulmonaires, principalement la pneumonie, à l'aide desdites compositions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2020117776 | 2020-05-29 | ||
| RU2020117776A RU2739573C1 (ru) | 2020-05-29 | 2020-05-29 | Стабильная водная фармацевтическая композиция для ингаляций, содержащая гексапептид |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021242142A1 true WO2021242142A1 (fr) | 2021-12-02 |
Family
ID=74062953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2021/000221 WO2021242142A1 (fr) | 2020-05-29 | 2021-05-27 | Composition pharmaceutique aqueuse stable |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2739573C1 (fr) |
| WO (1) | WO2021242142A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2770364C1 (ru) * | 2022-02-04 | 2022-04-15 | Федеральное Государственное Бюджетное Учреждение Науки "Научный Центр Биомедицинских Технологий Федерального Медико-Биологического Агентства" | Способ лечения болезней легких ингаляционным введением мезенхимальных стромальных клеток и гексапептида |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60853A (uk) * | 2003-03-18 | 2003-10-15 | Віталій Іванович Ляховський | Спосіб лікування субатрофічних і атрофічних захворювань верхніх дихальних шляхів |
| RU2241488C1 (ru) * | 2003-11-10 | 2004-12-10 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Раствор даларгина для инъекций |
| RU2413528C2 (ru) * | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
| RU2521199C1 (ru) * | 2013-03-06 | 2014-06-27 | Антон Евгеньевич Стрекалов | Фармацевтическая композиция для профилактики и лечения сосудистых нарушений и нейропатий |
| RU2657416C1 (ru) * | 2017-02-20 | 2018-06-13 | Общество с ограниченной ответственностью "АЛВИЛС" | Способ лечения эндотелиальной дисфункции |
| RU2672888C1 (ru) * | 2018-04-18 | 2018-11-20 | Пивипи Лабс Пте. Лтд. | Противовирусное иммунотропное средство для лечения ОРВИ |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60853U (ru) * | 2011-01-04 | 2011-06-25 | Харьковская Медицинская Академия Последипломного Образования | Способ экспресс-диагностики психоэмоциональных нарушений у спортсменов, которые занимаются экстремальными видами спорта |
-
2020
- 2020-05-29 RU RU2020117776A patent/RU2739573C1/ru active
-
2021
- 2021-05-27 WO PCT/RU2021/000221 patent/WO2021242142A1/fr active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60853A (uk) * | 2003-03-18 | 2003-10-15 | Віталій Іванович Ляховський | Спосіб лікування субатрофічних і атрофічних захворювань верхніх дихальних шляхів |
| RU2241488C1 (ru) * | 2003-11-10 | 2004-12-10 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Раствор даларгина для инъекций |
| RU2413528C2 (ru) * | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
| RU2521199C1 (ru) * | 2013-03-06 | 2014-06-27 | Антон Евгеньевич Стрекалов | Фармацевтическая композиция для профилактики и лечения сосудистых нарушений и нейропатий |
| RU2657416C1 (ru) * | 2017-02-20 | 2018-06-13 | Общество с ограниченной ответственностью "АЛВИЛС" | Способ лечения эндотелиальной дисфункции |
| RU2672888C1 (ru) * | 2018-04-18 | 2018-11-20 | Пивипи Лабс Пте. Лтд. | Противовирусное иммунотропное средство для лечения ОРВИ |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2739573C1 (ru) | 2020-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2522365B1 (fr) | Compositions comprenant de l'azélastine et leurs procédés d'utilisation | |
| US11844823B2 (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
| RU2728939C1 (ru) | Применение даларгина для производства средств лечения коронавирусной инфекции covid-19 | |
| DK2536412T3 (en) | An inhalable PHARMACEUTICAL COMPOSITION | |
| RU2739573C1 (ru) | Стабильная водная фармацевтическая композиция для ингаляций, содержащая гексапептид | |
| KR101778814B1 (ko) | 포모테롤 및 베클로메타손 디프로피오네이트의 약학적 에어로졸 제제 | |
| US20070254928A1 (en) | Use of Roflumilast for the Prophylaxis or Treatment of Emphysema | |
| US9539248B2 (en) | Agent for ameliorating chronic obstructive pulmonary disease | |
| RU2737799C1 (ru) | Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6 | |
| US20220105119A1 (en) | Delivery of aerosolized micromolar composition concentrations | |
| JP5908884B2 (ja) | 気道炎症及び粘液線毛輸送機能異常治療用のエアロゾル化したダプソン | |
| RU2728938C1 (ru) | Применение даларгина для производства лекарственных средств профилактики пневмонии | |
| WO2021211006A1 (fr) | Hexapeptide inhalé destiné au traitement de maladies respiratoires liées à l'interleukine-6 | |
| EA043664B1 (ru) | Бета-шпилечные пептидомиметики, обладающие ингибирующей активностью в отношении эластазы, и содержащие их лекарственные формы в виде аэрозоля |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21811837 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21811837 Country of ref document: EP Kind code of ref document: A1 |